First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
“We are excited to have dosed the first patient in this first-in-human clinical trial, which will evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BDC-3042 in a diverse set of advanced cancers,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. “BDC-3042 is a monoclonal antibody that repolarizes tumor-associated macrophages (TAMs) to attack tumor cells and is the first-in-class Dectin-2 agonist. As Dectin-2 gene expression is elevated in TAMs across a broad range of solid tumor types, we see potential for this novel immunotherapy to be used for a wide range of cancers. We are enthusiastic to advance our second innovative immunotherapy program to the clinic with a focus on providing breakthroughs for patients.”
Share:
More News
Pnina Fishman, CSO & Chairperson of Can-Fite BioPharma, commented: “We are pleased to offer this compassionate use program with Namodenoson for eligible patient in the US to address the unmet medical needs for pancreatic cancer. Initiating this program is another milestone achieved for Namodenoson, and concurrently to our ongoing Phase
“We are deeply disappointed by these results from our Phase 1 trial. Despite continuing to demonstrate differentiated safety as a more combinable ADC, updated efficacy data suggest that treatment with EO-3021 does not meet our bar for success and is insufficient to provide patients a competitive benefit-risk profile compared to
Søren Bregenholt, CEO of Alligator, commented: “The FDA’s recognition of HLX22/AC101’s potential with Orphan Drug Designation is a notable recognition. While Alligator’s is not directly involved in the development of HLX22/AC101, we continue to follow its progress as it potentially represents future income to Alligator.”
“At Servier, we are dedicated to transforming patient care in areas with significant unmet needs. Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies, as we believe we can serve more people by helping the right patients find the right treatment, at the right time,” said
